Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
5.440
+0.040 (+0.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fate Therapeutics
< Previous
1
2
3
4
Next >
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
September 18, 2023
Via
Investor Brand Network
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 29, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 22, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 01, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
October 25, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming September Investor Conferences
August 31, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
August 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
July 28, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
June 30, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
June 21, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
June 08, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
June 05, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.